Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424759 | 0.96 | MPL (0.30) | MPLCCNCCDK8HASPIN | |
| SCHEMBL425868 | 0.91 | CCNC (0.31) | CCNCCDK8HASPIN | |
| SCHEMBL431760 | 0.83 | NR1H2 (0.32) | MAPKAPK2 | |
| SCHEMBL428449 | 0.81 | MAPKAPK2 (0.51) | MAPKAPK2 | |
| SCHEMBL431381 | 0.81 | MAPKAPK2 (0.40) | MAPKAPK2 | |
| SCHEMBL428413 | 0.81 | MAPKAPK2 (0.51) | MPLMAPKAPK2 | |
| SCHEMBL424661 | 0.81 | MAPKAPK2 (0.40) | MPLMAPKAPK2 | |
| SCHEMBL428609 | 0.81 | MAPKAPK2 (0.42) | MPLMAPKAPK2 | |
| SCHEMBL430502 | 0.81 | — | — | |
| SCHEMBL432018 | 0.81 | MAPKAPK2 (0.39) | MPLMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112687878-B | Electrochemical device and electronic device | 东莞新能源科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-112687878-A | Electrochemical device and electronic device | 东莞新能源科技有限公司 | 2021-04-20 | — | — | CN | claimed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| CN-114555594-B | Substituted azacycles as TRMP modulators | 奇华顿股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-02-11 | — | — | US | disclosed |
| WO-2025003414-A1 | MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-02 | — | — | WO | disclosed |
| US-20240254138-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-01 | — | — | US | disclosed |
| CN-118324693-A | Piperazine compound, preparation method thereof, pharmaceutical composition and application | 东南大学 | 2024-07-12 | — | — | CN | disclosed |
| EP-4305040-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| CN-117222644-A | 2- ((4- ((S) -2- (4-chloro-2-fluorophenyl) -2-methylbenzo [ d ] [1,3] dioxol-4-yl) piperidin-1-yl) methyl) -1- (((S) -oxetan-2-yl) methyl) -1H-imidazole derivatives as GLP1 receptor activators for the treatment of obesity | 诺华股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| CN-101687869-A | Tetracyclic lactam derivatives as MK2 inhibitors | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254138-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CDK2, CCNK | MPL 393/4885CCNC 11/4885CDK8 10/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | MPL 447/4885CCNC 2418/4885CDK8 241/4885 |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | AHR, ARNT, NQO1 | MPL 407/4885CCNC 2220/4885CDK8 827/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MPL 132/4885CCNC 283/4885CDK8 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.